MX345150B - Antigenos ampliamente reactivos computacionalmente optimizados para virus de influenza h5n1 y h1n1. - Google Patents

Antigenos ampliamente reactivos computacionalmente optimizados para virus de influenza h5n1 y h1n1.

Info

Publication number
MX345150B
MX345150B MX2014011387A MX2014011387A MX345150B MX 345150 B MX345150 B MX 345150B MX 2014011387 A MX2014011387 A MX 2014011387A MX 2014011387 A MX2014011387 A MX 2014011387A MX 345150 B MX345150 B MX 345150B
Authority
MX
Mexico
Prior art keywords
polypeptides
influenza
optimized
broadly reactive
influenza viruses
Prior art date
Application number
MX2014011387A
Other languages
English (en)
Other versions
MX2014011387A (es
Inventor
M Ross Ted
J Crevar Corey
M Carter Donald
Original Assignee
Univ Of Pittsburgh - Of The Commonwealth System Of Higher Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Of Pittsburgh - Of The Commonwealth System Of Higher Education filed Critical Univ Of Pittsburgh - Of The Commonwealth System Of Higher Education
Publication of MX2014011387A publication Critical patent/MX2014011387A/es
Publication of MX345150B publication Critical patent/MX345150B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a la generación de polipéptidos HA de influenza H5N1 y H1N1 optimizados para inducir una respuesta inmune ampliamente reactiva a los aislados de virus de influenza. Los polipéptidos HA optimizados se desarrollaron a través de una serie de alineaciones de proteína HA, y la generación subsecuente de secuencias de consenso, en base a los aislados de influenza H5N1 y H1N1. Se proporcionan en la presente polipéptidos HA de influenza H5N1 y H1N1 optimizados, y composiciones, proteínas de fusión y VLPs que comprenden los polipéptidos HA. Además se proporcionan secuencias de ácido nucleico optimizadas en codón que codifican los polipéptidos HA. También se proporcionan por la presente descripción métodos para inducir una respuesta inmune contra el virus de influenza en un sujeto.
MX2014011387A 2012-03-30 2013-03-12 Antigenos ampliamente reactivos computacionalmente optimizados para virus de influenza h5n1 y h1n1. MX345150B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261617815P 2012-03-30 2012-03-30
PCT/US2013/030530 WO2013148164A1 (en) 2012-03-30 2013-03-12 Computationally optimized broadly reactive antigens for h5n1 and h1n1 influenza viruses

Publications (2)

Publication Number Publication Date
MX2014011387A MX2014011387A (es) 2014-10-14
MX345150B true MX345150B (es) 2017-01-18

Family

ID=49261015

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014011387A MX345150B (es) 2012-03-30 2013-03-12 Antigenos ampliamente reactivos computacionalmente optimizados para virus de influenza h5n1 y h1n1.

Country Status (15)

Country Link
US (2) US9212207B2 (es)
EP (1) EP2831094B1 (es)
JP (1) JP2015513902A (es)
KR (1) KR20150004800A (es)
CN (1) CN104395336B (es)
AU (1) AU2013240365B2 (es)
BR (1) BR112014023900A2 (es)
CA (1) CA2868330A1 (es)
HK (1) HK1203522A1 (es)
IN (1) IN2014DN07399A (es)
MX (1) MX345150B (es)
MY (1) MY166953A (es)
RU (2) RU2639551C2 (es)
SG (1) SG11201406153XA (es)
WO (1) WO2013148164A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883171B2 (en) * 2010-09-14 2014-11-11 University of Pittsburgh—of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for influenza
KR20140047069A (ko) 2011-06-20 2014-04-21 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 계산에 최적화된 광범위 반응을 나타내는 ｈ１ｎ１ 인플루엔자를 위한 항원
IN2015DN03070A (es) 2012-11-27 2015-10-02 Univ Pittsburgh
US20140286981A1 (en) * 2013-03-14 2014-09-25 Wisconsin Alumni Research Foundation Broadly reactive mosaic peptide for influenza vaccine
US10548965B2 (en) * 2014-12-19 2020-02-04 Oregon Health & Science University Synergistic co-administration of computationally optimized broadly reactive antigens for human and avian H5N1 influenza
US10220086B2 (en) 2014-12-19 2019-03-05 Oregon Health & Science University Synergistic co-administration of computationally optimized broadly reactive antigens for H1N1 influenza
CA2987939A1 (en) 2015-06-02 2016-12-08 Sanofi Pasteur Inc. Engineered influenza antigenic polypeptides and immunogenic compositions thereof
CA2986701A1 (en) * 2015-06-09 2016-12-15 Sanofi Pasteur, Inc. Methods of optimizing nucleotide sequences encoding engineered influenza proteins
US20200237898A1 (en) * 2015-09-21 2020-07-30 Oregon Health & Science University Vaccines intelligently produced by epitope recombination (viper) for influenza
CA3026096A1 (en) 2016-06-02 2017-12-07 Sanofi Pasteur Inc. Engineered influenza antigenic polypeptides and immunogenic compositions thereof
MA45159A (fr) 2016-06-03 2019-04-10 Sanofi Pasteur Inc Polypeptides d'hémagglutinine d'influenza modifiés
WO2019191257A1 (en) * 2018-03-28 2019-10-03 Sanofi Pasteur Inc. Methods of generating broadly protective vaccine compositions comprising hemagglutinin
EP3773709A4 (en) * 2018-03-28 2021-12-29 Sanofi Pasteur Inc. Methods of generating broadly protective vaccine compositions comprising neuraminidase
CN112512564A (zh) 2018-04-03 2021-03-16 赛诺菲 铁蛋白蛋白
WO2019195284A1 (en) 2018-04-03 2019-10-10 Sanofi Antigenic influenza-ferritin polypeptides
MX2021005257A (es) * 2018-11-06 2021-06-18 Boehringer Ingelheim Vetmedica Gmbh Composicion inmunogenica contra el subtipo h5 del virus de la influenza aviar.

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000885A2 (en) 2000-06-23 2002-01-03 American Cyanamid Company Assembly of wild-type and chimeric influenza virus-like particles (vlps)
US20050181459A1 (en) 2002-06-11 2005-08-18 Matthew Baker Method for mapping and eliminating T cell epitopes
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
CA2598884A1 (en) 2005-02-24 2006-10-05 University Of Massachusetts Influenza nucleic acids, polypeptides, and uses thereof
CA2615658A1 (en) 2005-07-19 2007-01-25 Dow Global Technolgies Inc. Recombinant flu vaccines
CA2633793A1 (en) 2005-12-19 2007-06-28 Novartis Vaccines And Diagnostics S.R.L. Methods of clustering gene and protein sequences
US20080045472A1 (en) 2006-03-31 2008-02-21 Council Of Scientific And Industrial Research Bharat Biotech Targets for human micro rnas in avian influenza virus (h5n1) genome
WO2008028946A2 (en) 2006-09-07 2008-03-13 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
US8030029B2 (en) * 2007-01-23 2011-10-04 Academia Sinica Flu vaccines and methods of use thereof
EP2185195A2 (en) 2007-08-16 2010-05-19 Tripep Ab Immunogen platform
JP5705545B2 (ja) 2007-11-12 2015-04-22 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア インフルエンザウイルスの複数のサブタイプに対する新規ワクチン
KR101956910B1 (ko) 2008-01-21 2019-03-12 메디카고 인코포레이티드 헤마글루티닌을 발현하는 트랜스제닉 식물에서 생산된 재조합 인플루엔자 바이러스-유사 입자(ＶＬＰｓ)
US7981428B2 (en) 2008-01-23 2011-07-19 Academia Sinica Flu vaccines and methods of use thereof
WO2010036970A2 (en) 2008-09-25 2010-04-01 Fraunhofer Usa, Inc. Influenza vaccines, antigens, compositions, and methods
US20110177122A1 (en) 2008-09-26 2011-07-21 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services Dna prime/activated vaccine boost immunization to influenza virus
CA2757030C (en) 2009-04-03 2019-01-15 Merial Limited Vectors comprising newcastle disease viruses and compositions thereof
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
US8883171B2 (en) 2010-09-14 2014-11-11 University of Pittsburgh—of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for influenza
KR20140047069A (ko) 2011-06-20 2014-04-21 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 계산에 최적화된 광범위 반응을 나타내는 ｈ１ｎ１ 인플루엔자를 위한 항원
EP2812348A4 (en) * 2012-02-07 2015-12-30 Univ Pittsburgh ANTIGENS WITH BROAD SPECTRUM OPTIMIZED IN SILICO FOR INFLUENZA VIRUSES OF TYPE H3N2, H2N2 AND B
CN104144941B (zh) 2012-02-13 2017-06-09 高等教育联邦***-匹兹堡大学 以计算方式优化的人和禽h5n1流感的广泛反应性抗原
IN2015DN03070A (es) 2012-11-27 2015-10-02 Univ Pittsburgh

Also Published As

Publication number Publication date
CA2868330A1 (en) 2013-10-03
RU2017141447A (ru) 2019-02-13
EP2831094A4 (en) 2015-10-14
JP2015513902A (ja) 2015-05-18
US20160279226A1 (en) 2016-09-29
RU2014142785A (ru) 2016-05-20
KR20150004800A (ko) 2015-01-13
AU2013240365B2 (en) 2017-03-30
CN104395336A (zh) 2015-03-04
AU2013240365A1 (en) 2014-10-23
MX2014011387A (es) 2014-10-14
HK1203522A1 (en) 2015-10-30
RU2639551C2 (ru) 2017-12-21
US9212207B2 (en) 2015-12-15
EP2831094A1 (en) 2015-02-04
SG11201406153XA (en) 2014-10-30
CN104395336B (zh) 2018-01-23
MY166953A (en) 2018-07-25
BR112014023900A2 (pt) 2020-11-24
IN2014DN07399A (es) 2015-04-24
US9555095B2 (en) 2017-01-31
WO2013148164A1 (en) 2013-10-03
US20150017196A1 (en) 2015-01-15
EP2831094B1 (en) 2018-06-13

Similar Documents

Publication Publication Date Title
MX345150B (es) Antigenos ampliamente reactivos computacionalmente optimizados para virus de influenza h5n1 y h1n1.
EP3199545A3 (en) Computationally optimized broadly reactive antigens for h1n1 influenza
MY180109A (en) Computationally optimized broadly reactive antigens for human and avian h5n1 influenza
CA2863981A1 (en) Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses
MX2013014109A (es) Proteina de fusion que comprende el mutante crm197 no toxico de toxina de difteria.
AU2013352179A8 (en) Computationally optimized broadly reactive antigens for H1N1 influenza
MX2013008836A (es) Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso.
MY182643A (en) Chimeric influenza virus-like particles comprising hemagglutinin
EA201891712A2 (ru) Молекулы нуклеиновых кислот гриппа и вакцины, изготовленные из них
MY192714A (en) Antibody neutralizing human respiratory syncytial virus
MX2014004214A (es) Moleculas de acido ribonucleico policistronicas auto-replicantes recombinantes.
MY170927A (en) Influenza virus vaccines and uses thereof
MX2021006342A (es) Mutantes de virus de influenza y usos para los mismos.
MX343830B (es) Molecula de acido nucleico que codifica la proteina nuclear del virus de la hepatitis b y vacuna que comprende la misma.
RU2015138530A (ru) Комбинированная вакцина против респираторно-синцитиального вируса и вируса гриппа
WO2012047679A3 (en) Consensus antigen constructs and vaccines made there form, and methods of using same to treat malaria
NZ702146A (en) Peptides derived from viral proteins for use as immunogens and dosage reactants
MX2013013228A (es) Particulas similares a virus y proceso para prepararlas.
MX363464B (es) Vacunas contra influenza h5.
MX2019007924A (es) Vacunas contra la influenza.
WO2013049535A3 (en) Influenza vaccine
IN2015DN01342A (es)
MX356408B (es) Metodo para obtener proteinas recombinantes con capacidad inmunogenica en pichia pastoris y su uso en una preparacion de vacunas contra virus de influenza.
RU2010121411A (ru) Рекомбинантная вакцина против вируса "свиного" гриппа h1n1 и способ ее получения
TN2010000332A1 (en) Recombinant influenza virus-like particles (vlps)produced in transgenic plants expressing hemagglutinin

Legal Events

Date Code Title Description
FG Grant or registration